Dexcom Expands AID Partnership Into The Netherlands: Introducing the Omnipod 5 and Dexcom G6 for Easier Diabetes Management
EDINBURGH, Scotland - DexCom, Inc. (Nasdaq: DXCM), a global leader in real-time continuous glucose monitoring for people with diabetes, is thrilled to announce the expansion of its partnership into the Netherlands. This development brings hope and enhanced diabetes management to people living with Type 1 diabetes in the country.
Type 1 diabetes is a chronic disease that affects the body’s ability to produce insulin, a hormone necessary to regulate blood sugar levels. Currently, more than 100,000 individuals in the Netherlands are impacted by this condition, with an additional estimated 10,000 new diagnoses each year. Dexcom’s commitment to improving the lives of people with diabetes remains strong, and their latest innovation, the Omnipod 5 integrated with the Dexcom G6 Continuous Glucose Monitor (CGM), aims to revolutionize diabetes management for individuals in the Netherlands.
The Omnipod 5 is a tubeless Hybrid Closed Loop system (HCL) designed to provide an easier and more seamless diabetes management experience. This state-of-the-art system combines the benefits of a traditional insulin pump with the continuous glucose monitoring capabilities of Dexcom’s G6 CGM. The Omnipod 5 system allows for automatic insulin adjustments based on real-time blood sugar data, offering individuals greater control and peace of mind in managing their condition.
By integrating Dexcom’s G6 CGM with the Omnipod 5, individuals with Type 1 diabetes in the Netherlands will enjoy continuous and accurate glucose monitoring. The Dexcom G6 CGM is renowned for its accuracy and reliability, providing real-time glucose readings every five minutes without the need for fingerstick calibration. With this system, users can receive alerts and notifications directly to their smartphones, allowing them to adjust their diabetes management approach promptly.
The partnership between Dexcom and the Netherlands marks an important step forward in diabetes care. By offering this innovative solution, individuals in the Netherlands will have access to a comprehensive and sophisticated system that has the potential to improve their quality of life significantly. Managing Type 1 diabetes can be a challenging and demanding task, but with the Omnipod 5 and Dexcom G6, individuals can experience a more streamlined approach to diabetes management, enabling them to live life to the fullest.
The introduction of the Omnipod 5 and Dexcom G6 in the Netherlands showcases Dexcom’s continued commitment to expanding its global reach and improving the lives of individuals with diabetes worldwide. As a company known for its cutting-edge technology and industry expertise, Dexcom strives to develop innovative solutions that empower individuals to better manage their condition.
In conclusion, the partnership between Dexcom and the Netherlands will undoubtedly make a significant impact on the lives of individuals living with Type 1 diabetes in the country. The Omnipod 5 and Dexcom G6 system offers a new level of convenience and control, allowing users to navigate their diabetes management journey with ease and confidence. With this remarkable collaboration, Dexcom reinforces its position as a global leader in continuous glucose monitoring and diabetes management.
Comments